These data suggest that high MLC2 (MYL9) expression and/or activation (p-MLC2) in melanoma cells together with immunosuppressive populations and higher collagen densities identify therapy-resistant melanomas, suggesting their potential as biomarkers. The gene discussed is MYL12B; the disease is melanoma.